GMPs Guide COVID-19 Vaccine Manufacturing

Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.

Major bio/pharmaceutical companies and contract service providers leading the charge to bring COVID-19 vaccines to market are familiar with established good manufacturing practices (GMPs). To support manufacturers in the rush to develop a vaccine, FDA, in June 2020, released industry guidance highlighting the development and licensure of COVID-19 vaccines.

Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 9–10

Citation

When referring to this article, please cite it as F. Mirasol, “GMPs Guide COVID-19 Vaccine Manufacturing," BioPharm International Regulatory Sourcebook eBook (October 2020).

Articles in this issue

about 5 years ago

Article

Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies

about 5 years ago

Article

Viral Vector API Characterization of Product-Related Impurities

about 5 years ago

Article

Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?

about 5 years ago

Article

Tackling Cybersecurity Challenges in Legacy Systems

about 5 years ago

Article

Enhancing Process Validation for Sterile Liquid and Freeze-Dried Forms

about 5 years ago

Article

Due Diligence Assessment of CMC Activities

about 5 years ago

Article

Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

about 5 years ago

Article

Strong Quality Culture: A How-To for Busy Managers

about 5 years ago

Article

Resources, Guidelines, and Guidance Documents

about 5 years ago

Article

Regulatory and Standard Setting Organizations

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!